SCHEDULE 13G/A: Great Point Partners and Affiliates Disclose 2.98% Passive Stake in Neurogene Inc.

Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have jointly disclosed a passive beneficial ownership of 2.98% of Neurogene Inc.'s common stock as of December 31, 2024.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Neurogene Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 442,761 shares of Neurogene Inc.'s Common Stock.
• This ownership represents 2.98% of the outstanding shares of Neurogene Inc.'s Common Stock.
• The percentage is calculated based on 14,854,725 shares outstanding, as reported by Neurogene Inc. in its Form 10-Q filed with the SEC on November 18, 2024.
• The Reporting Persons have shared voting power and shared dispositive power over all 442,761 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, with no positive or negative operational or financial news for the company.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm and its principals in a publicly traded biotechnology company, Neurogene Inc. It reflects a passive investment stake below the 5% threshold that would typically trigger more active investor engagement or control intent.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes in the company.

Key Dates

Keywords

Neurogene Inc., Great Point Partners, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment, Passive Stake